Currently<unk> , being a subtype of PTCL, is treated similarly to B-cell lymphomas. However, in recent years, scientists have developed techniques to better recognize the different types of lymphomas, such as PTCL. It is now understood that PTCL behaves differently from B-cell lymphomas and therapies are being developed that specifically target these types of lymphoma. Currently, however, there are no therapies approved by the U.S. Food and Drug Administration (FDA) specifically for PTCL. Anthracycline-containing chemotherapy regimens are commonly offered as the initial therapy. Some patients may receive a stem cell transplant. Novel approaches to the treatment of PTCL in the relapsed or refractory setting are under investigation.
Aggressive NK-cell leukemia
Precursor T-lymphoblastic lymphoma
Blastic plasmacytoid dendritic cell neoplasm
Angioimmunoblastic T-cell lymphoma
Peripheral T-cell lymphoma
B-cell prolymphocytic leukemia
T-cell prolymphocytic leukemia
Precursor B-cell lymphoblastic leukemia